CN114728919B - MrgprX2拮抗剂及其用途 - Google Patents

MrgprX2拮抗剂及其用途

Info

Publication number
CN114728919B
CN114728919B CN202080082802.5A CN202080082802A CN114728919B CN 114728919 B CN114728919 B CN 114728919B CN 202080082802 A CN202080082802 A CN 202080082802A CN 114728919 B CN114728919 B CN 114728919B
Authority
CN
China
Prior art keywords
compound
skin
composition
acid
atopic dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080082802.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728919A (zh
Inventor
费尔达·切维克巴斯
克里斯托弗·皮尔森
劳拉·格里夫
妮娜·康纳利·乌尔西尼奥娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of CN114728919A publication Critical patent/CN114728919A/zh
Application granted granted Critical
Publication of CN114728919B publication Critical patent/CN114728919B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080082802.5A 2019-11-05 2020-11-05 MrgprX2拮抗剂及其用途 Active CN114728919B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931186P 2019-11-05 2019-11-05
US62/931,186 2019-11-05
US201962931576P 2019-11-06 2019-11-06
US62/931,576 2019-11-06
US202063046481P 2020-06-30 2020-06-30
US63/046,481 2020-06-30
PCT/US2020/059228 WO2021092264A1 (en) 2019-11-05 2020-11-05 MrgprX2 ANTAGONISTS AND USES THEREOF

Publications (2)

Publication Number Publication Date
CN114728919A CN114728919A (zh) 2022-07-08
CN114728919B true CN114728919B (zh) 2025-12-30

Family

ID=73740488

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080082802.5A Active CN114728919B (zh) 2019-11-05 2020-11-05 MrgprX2拮抗剂及其用途

Country Status (8)

Country Link
US (1) US20230002336A1 (https=)
EP (1) EP4055011A1 (https=)
JP (1) JP7787811B2 (https=)
CN (1) CN114728919B (https=)
AU (1) AU2020380926A1 (https=)
CA (1) CA3159633A1 (https=)
IL (1) IL292693A (https=)
WO (1) WO2021092264A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
KR20250121245A (ko) * 2024-02-02 2025-08-12 삼진제약주식회사 MRGPRX2 (Mas-related G-protein coupled receptor member X2) 길항제로서 신규 화합물 및 이를 포함하는 약학적 조성물
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
TW202547469A (zh) 2024-04-19 2025-12-16 日商杏林製藥股份有限公司 Mrgprx2拮抗劑、包含mrgprx2拮抗劑之醫藥組成物及治療mrgprx2媒介疾病或病症之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152442A (en) * 1975-06-05 1979-05-01 Lilly Industries Limited Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3272640D1 (en) * 1982-01-22 1986-09-18 Basf Ag Thiadiazole derivatives, process for their preparation, and their use in combatting unwanted plant growth
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
GB0308511D0 (en) * 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
EP1658072A4 (en) * 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases
DE102004009933A1 (de) * 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
EP2125799A1 (en) * 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2010013705A (es) * 2008-06-13 2011-02-25 Bayer Cropscience Ag Nuevas amidas y tioamidas heteroaromaticas como plaguicidas.
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US8377639B2 (en) * 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
PT2673285T (pt) * 2010-12-09 2017-10-19 Wockhardt Ltd Resumo
CA2850551A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
ES2670517T3 (es) * 2013-01-30 2018-05-30 Sumitomo Chemical Company, Limited Compuesto de amida, un agente de control de plagas de artrópodos y un método para controlar las plagas de artrópodos
EP3444251B1 (en) * 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CA3055194A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"RN：2373941-16-1、2373325-95-0、2193792-05-9、2040582-49-6、1333564-20-7、2071964-14-0、1384798-21-3、2205035-75-0、2190810-48-9、2194029-28-0、2195916-52-8、2210010-66-3、2370787-18-9";ACS;《STN Registry数据库》;20190904 *
"RN：345614-53-1";ACS;《STN Registry数据库》;20010712 *
RN：2373852-96-9、237378527-2、2372800-30-9、2072672-14-9、2071656-21-6、1795510-24-5、1301765-43-4、1355717-46-2、1389735-91-4、2059876-46-7、1227730-50-8、1277689-92-5、1390176-03-0、1957160-15-4、2060949-80-4、2068673-72-1、2068938-31-6、2068939-44-4、2069173-62-0、2069318-09-6、2069575-25-1、2071003-29-5、2071484-66-5、2071485-23-7、2071601-36-8、2071773-48-1、2072009-87-9、2072182-30-8、2072216-64-7、2072231-63-9、2072445-40-8、2072573-53-4、2072573-66-9、2072641-65-5、2072939-65-0、2072967-38-3、2305355-17-1、881939-98-6;ACS;《STN Registry数据库》;20190904 *

Also Published As

Publication number Publication date
JP2022554392A (ja) 2022-12-28
EP4055011A1 (en) 2022-09-14
IL292693A (en) 2022-07-01
JP7787811B2 (ja) 2025-12-19
US20230002336A1 (en) 2023-01-05
AU2020380926A1 (en) 2022-05-26
CN114728919A (zh) 2022-07-08
WO2021092264A1 (en) 2021-05-14
CA3159633A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
CN114845709B (zh) 用于治疗炎性病症的mrgprx2拮抗剂
CN114728919B (zh) MrgprX2拮抗剂及其用途
CN114901280B (zh) MrgprX2拮抗剂及其用途
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
CZ284363B6 (cs) Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů
CA3198489A1 (en) Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
KR20160108828A (ko) 신속하게 붕괴되는 제형 및 사용 방법
KR101510595B1 (ko) 유제놀을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물
WO2012057103A1 (ja) 医薬組成物
JP2012144564A (ja) 医薬組成物
ES2288117B1 (es) Composicion farmaceutica solida de gabapentina.
CN110582278B (zh) 药物组合物及其用途
JP7813733B2 (ja) Ｉｒａｋ４阻害剤及びそれらの局所的使用方法
CN102614182A (zh) 一种复方氨酚肾素药物组合物脂质体固体制剂
KR20250005055A (ko) 아스피린 및 기타 nsaid의 고 침투성 전구약물을 이용한 심혈관 질환의 예방 또는 치료
KR101625926B1 (ko) 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 방법 및 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 개선된 약학적 조성물
JP4981194B2 (ja) 医薬組成物
WO2023224960A1 (en) Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
PHARMACEUTICS FORMULATION AND CHARACTERIZATION OF RIZATRIPTAN BENZOATE SUBLINGUAL TABLET WITH VARIOUS PERMEATION ENHANCERS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant